141 related articles for article (PubMed ID: 9120935)
1. Prostate cancer in Nigerians: facts and nonfacts.
Osegbe DN
J Urol; 1997 Apr; 157(4):1340-3. PubMed ID: 9120935
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
3. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer in Maiduguri.
Yawe KT; Tahir MB; Nggada HA
West Afr J Med; 2006; 25(4):298-300. PubMed ID: 17402521
[TBL] [Abstract][Full Text] [Related]
5. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
6. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey.
Hawk E; Breslow RA; Graubard BI
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):523-7. PubMed ID: 10815699
[TBL] [Abstract][Full Text] [Related]
7. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
8. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
9. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Sarma AV; McLaughlin JC; Wallner LP; Dunn RL; Cooney KA; Schottenfeld D; Montie JE; Wei JT
J Urol; 2006 Sep; 176(3):1108-13. PubMed ID: 16890703
[TBL] [Abstract][Full Text] [Related]
10. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
11. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
Coard KC; Skeete DH
BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
[TBL] [Abstract][Full Text] [Related]
12. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series.
Adolfsson J; Steineck G; Hedlund PO
Urology; 1997 Nov; 50(5):722-6. PubMed ID: 9372882
[TBL] [Abstract][Full Text] [Related]
13. Mass screening for prostate cancer in Korea: a population based study.
Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer incidence in guadeloupe, a French Caribbean archipelago.
Mallick S; Blanchet P; Multigner L
Eur Urol; 2005 Jun; 47(6):769-72. PubMed ID: 15925071
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of physical activity and incident and fatal prostate cancer.
Giovannucci EL; Liu Y; Leitzmann MF; Stampfer MJ; Willett WC
Arch Intern Med; 2005 May; 165(9):1005-10. PubMed ID: 15883238
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
17. [Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients].
Arrizabalaga Moreno M; García González JI; Diez Rodríguez JM; Esteban Artiaga R; Castro Pita M; Navarro Sebastian J; Mora Durbán M; Paniagua Andrés P
Actas Urol Esp; 1997 Oct; 21(9):852-61. PubMed ID: 9471868
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
19. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
[TBL] [Abstract][Full Text] [Related]
20. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
Aus G; Robinson D; Rosell J; Sandblom G; Varenhorst E;
Cancer; 2005 Mar; 103(5):943-51. PubMed ID: 15651057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
